5. Stoekenbroek RM, Lambert G, Cariou B, et al. Inhibiting PCSK9-biology beyond LDL control. Nat Rev Endocrinol, 2018, 15(1): 52-62. 6. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol, 2019, 16(3):15...
A method comprising administering an agent, for example a PCSK9 inhibitor, to a patient who suffers from fatty liver disease or is at risk of fatty liver disease, thereby reducing the risk of fatty liver disease, severity of fatty liver disease, symptoms of such disease, or signs of such ...
新一代降脂药物PCSK9抑制药研究进展 Progress Research of Novel Lipid-lowering Therapy of Proprotein Convertase Subtilisin/ kexin Type 9 Inhibitors 摘要 前蛋白转化酶枯草溶菌素9(PCSK9)是一种新发现的丝氨酸蛋白酶,属于前蛋白家族,由肝脏合成分泌后,可与细胞表面的低密度脂蛋白受体( LDLR)结合将其转运至溶酶体,...
Combination of cholesterol absorption inhibitors and/or PCSK9 inhibitors should be considered when LDL-C targets are not met after statin therapy. Early use of PCSK9 monoclonal antibodies has been shown to reduce ASCVD risk earlier and more significantly, with good safety for prolonged use (≥7 y...
Thisreview focuses on the latest research progress in and development of PCSK9 inhibitors.Key words: PCSK9 inhibitors; Evolocumab; Alirocumab; small interfering RNA作者简介:丘岳,女,副主任药师,主要从事临床药学与合理用药研究,E-mail:398455921@qq.com * 通信作者:黄振光,男,主任药师,主要从事医院药学与药...
The diabetogenic effect of statins has been well established by clinical trials, Mendelian randomisation studies and meta-analyses. According to large clinical trials, PCSK9 inhibitors (PCSK9i) have no deleterious impact on glucose metabolism. However, f
However, with the development of new types of PCSK9 inhibitors, there will be more efficient and economical drugs for clinicians to choose, such as antisense oligodeoxynucleotides, RNA interference drugs, vaccines, small molecule inhibitors. 展开 ...
Although therapeutic PCSK9 inhibition could theoretically have undesired effects by interfering with these non-cholesterol-related processes, studies of individuals with genetically determined reduced PCSK9 function and clinical trials of PCSK9 inhibitors have not revealed clinically meaningful adverse ...
PCSK9 (Proproteinkonvertase Subtilisin/Kexin Typ 9) bindet an den LDL („low-density lipoprotein“)-Rezeptor und führt in Leberzellen zu sei
The discovery of PCSK9 in 2003 and its identification as the third protagonist responsible for ADH opened many new avenues of research in the cardiovascula... NG Seidah - 《Current Pharmaceutical Design》 被引量: 100发表: 2013年 Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in th...